The promise of tumor-targeted gene-based delivery of immune-activating cytokinesPublished: July 4, 2019
Cellular Immuno-Oncology 4.0
Luigi Naldini is the Director of the San Raffaele Telethon Institute for Gene Therapy and Professor at the San Raffaele University and Milan, Italy. He has pioneered the development and applications of lentiviral vectors for gene therapy and contributed to advance targeted genome editing in cell and gene therapy. He is member of EMBO, past President of ESGCT, and received the Outstanding Achievement Award from ASGCT in 2014 and from ESGCT in 2015, the Beutler Prize from ASH in 2017 and the 2019 Jeantet-Collen Prize for Translational Medicine.DOI: 10.18609/cgti.2019.074
Citation: Cell & Gene Therapy Insights 2019; 5(5), 653-659.